Transition of maternal serum concentration of digoxin and flecainide in the third trimester-A case report of fetal supraventricular tachycardia with hydrops

Hirokazu Takatsuka; Kayo Wakabayashi; Shingo Yamazaki; Hirokazu Tanaka; Akiko Omoto; Takaaki Suzuki; Makio Shozu; Itsuko Ishii

doi:10.1002/ccr3.3992

Transition of maternal serum concentration of digoxin and flecainide in the third trimester-A case report of fetal supraventricular tachycardia with hydrops

Clin Case Rep. 2021 Mar 27;9(5):e03992. doi: 10.1002/ccr3.3992. eCollection 2021 May.

Authors

Hirokazu Takatsuka¹, Kayo Wakabayashi¹, Shingo Yamazaki¹, Hirokazu Tanaka², Akiko Omoto³, Takaaki Suzuki^{1

4}, Makio Shozu⁵, Itsuko Ishii^{1

4}

Affiliations

¹ Division of Pharmacy Chiba University Hospital Chiba Japan.
² Department of Obstetrics and Gynecology International University of Health and Welfare Narita Hospital Chiba Japan.
³ Department of Maternal-Fetal Medicine Chiba University Hospital Chiba Japan.
⁴ Graduate School of Pharmaceutical Sciences Chiba University Chiba Japan.
⁵ Department of Reproductive Medicine Graduate School of Medicine Chiba University Chiba Japan.

Abstract

When transplacental therapy is conducted, the maternal serum concentrations of digoxin and flecainide may fluctuate throughout third trimester. Therefore, TDM may be effective in improving the efficacy and safety of treatment.

Keywords: fetus; flecainide; hydrops; supraventricular tachycardia; therapeutic drug monitoring; third trimester; transplacental treatment.

Publication types

Case Reports